Retatrutide Stability: Storage, Reconstitution, and Shelf Life

Retatrutide stability splits into three questions with three different answers. The sealed lyophilized vial runs on the supplier’s own label date. The reconstituted vial runs on temperature, light, and the water used, with no published degradation figure behind it, because the retatrutide trial record reports efficacy and safety endpoints rather than vial chemistry. The in-use window is arithmetic: at the 4 mg once-weekly step used in the phase 2 obesity trial (PMID 37366315), a 20 mg vial has to survive 20 ÷ 4 = 5 weeks in solution.

That third number is the one that decides everything else, and it is the one most listings never mention.

Is there published stability data for retatrutide?

Not in the clinical literature that covers the compound. The phase 2 obesity trial enrolled 338 adults on subcutaneous retatrutide at 1 mg, 4 mg, 8 mg, or 12 mg once weekly for 48 weeks, with percentage change in body weight at 24 weeks as the primary endpoint (Jastreboff et al., NEJM 2023). Nothing in that report, or in the TRIUMPH phase 3 program design covering more than 5,800 participants across four weekly-dosing studies, describes how a vial behaves on a shelf.

Trial material is manufactured, packaged, and cold-chained by the sponsor; the stability work sits in regulatory filings that are not part of the published record. So a shelf-life number attached to a research-grade vial is a supplier specification, not a trial result. Read it as a claim with a company behind it, and check whether that company says under what conditions it was measured.

Research use only. What follows is arithmetic on vial contents, not a handling instruction.

How does reconstitution volume change what a unit holds?

Two variables set every downstream figure: how much peptide is in the vial and how much bacteriostatic water goes in. Concentration = vial mg ÷ mL added. Converting for a U-100 syringe, where 1 mL = 100 units and 1 mg = 1,000 mcg: mcg per unit = (mg/mL × 1,000) ÷ 100.

Vial (mg)	BAC water (mL)	Concentration (mg/mL)	Per U-100 unit (mcg)	Units to draw 4 mg
10	1	10	100	40
10	2	5	50	80
10	3	3.33	33.3	120
20	2	10	100	40
20	3	6.67	66.7	60
20	4	5	50	80

Concentrations and per-unit figures computed from the 10 mg and 20 mg vial formats this register tracks (catalog check, September 2026), using the formulas above. The final column converts the 4 mg weekly dose arm from the phase 2 trial cited above (PMID 37366315) into syringe units at each concentration.

Worked through once in full: a 10 mg vial with 2 mL of bacteriostatic water gives 10 ÷ 2 = 5 mg/mL. That is 5,000 mcg/mL, and 5,000 ÷ 100 units = 50 mcg per unit. A 4 mg volume is 4,000 ÷ 50 = 80 units, or 0.8 mL.

The 10 mg / 3 mL row is the one to notice: 120 units exceeds a single 100-unit syringe, so that fill volume forces two draws per aliquot and two stopper punctures where one would do. Fill volume is a handling decision before it is a math decision, which is why picking a fill volume for a 10 mg vial is worth settling before the stopper is pierced rather than after. A calculator such as peptcalc.com will reproduce these conversions independently.

How long does a vial have to stay stable?

Divide vial content by the weekly amount drawn. The dose steps below are the arms studied in the phase 2 trial, which used once-weekly subcutaneous administration (PMID 37366315); the weeks column is vial mg ÷ weekly mg.

Weekly amount (mg)	Weeks per 10 mg vial	Weeks per 20 mg vial
1	10.0	20.0
4	2.5	5.0
8	1.25	2.5
12	0.83	1.67

In-use duration computed as vial mg ÷ weekly mg, using the 1, 4, 8 and 12 mg once-weekly arms from the phase 2 trial cited above and the 10 mg and 20 mg vial formats tracked here.

The spread runs from under a week to twenty weeks from the same two vial sizes. At 12 mg weekly a 20 mg vial is exhausted in under two weeks, so the stated post-reconstitution window has almost no work to do. At 1 mg weekly, that same vial sits in solution for 20 weeks, which is longer than any window this register has seen stated on a retatrutide listing. The stability question is only load-bearing at the low end of the dose range, and that is exactly where suppliers say least.

The honest move at the long end is to reconstitute less: split a 20 mg vial’s contents differently, or use the smaller format, rather than asking one solution to hold for twenty weeks. The split between lyophilized and reconstituted storage is what makes that work, since powder held under label conditions is not on the same clock as solution.

What does a shelf-life statement on a listing actually describe?

Four distinct things get printed under the same heading, and they are not interchangeable:

1. Manufacture or fill date. When the lyophilized material was produced. Sets the start of the powder’s clock.
2. COA test date. When purity and identity were measured on that batch. A COA dated well before the fill tells you the assay covers the bulk peptide, not the vial you hold.
3. Retest or expiry date for the sealed vial. The supplier’s claim about the powder under stated storage conditions. Ask which conditions: a date with no temperature attached is not a specification.
4. Post-reconstitution window. The supplier’s claim about the solution, usually the shortest number on the page and the one most often stated without any testing basis. Vendor phrasing varies enough that comparing how listings word post-reconstitution windows across suppliers is more informative than any single figure.

A listing that gives one date and no label for it has answered none of the four. Where two suppliers state different windows for the same nominal compound, they are describing different packaging, different preservative systems, or different levels of testing rigor, and both can be internally consistent.

What belongs in the record for a reconstituted vial?

Six fields, each of which makes a later figure recomputable:

• Batch or lot number as printed on the vial, matched against the COA header.
• Vial nominal content in mg.
• Volume and type of diluent added, in mL, with the preservative named.
• Resulting concentration in mg/mL, computed at the time of reconstitution.
• Date and time of reconstitution.
• Storage location and temperature, plus whether the vial sits in its outer carton, since light exposure during storage is handled at the packaging level rather than the vial level.

Vial content plus diluent volume is the pair that regenerates everything else. A vial labeled “10 mg, 2 mL BAC, 5 mg/mL, 11 Sep 2026” lets anyone recompute 50 mcg per unit months later; a vial labeled “reta 10” does not, and no storage condition recovers that information once the carton is discarded.